Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Dec 15;24(24):6112-6114.
doi: 10.1158/1078-0432.CCR-18-3178. Epub 2018 Oct 23.

Targeting Resistance to Targeted Therapies: Combating a Resilient Foe

Siddhartha Devarakonda  1   2 , Ramaswamy Govindan  3   2
Affiliations
Comment

Targeting Resistance to Targeted Therapies: Combating a Resilient Foe

Siddhartha Devarakonda et al. Clin Cancer Res. .

Abstract

While the advent of third-generation therapies has dramatically changed the treatment paradigm for EGFR-mutated lung cancer, resistance to these agents inevitably emerges. Understanding resistance mechanisms and their genomic underpinnings is crucial for developing innovative strategies that are capable of meaningfully prolonging patient survival.See related article by Le et al., p. 6195.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest:

RG has received honoraria for consulting from AbbVie, Genentech, Janssen, AstraZeneca, EMD Sereno, BMS, Pfizer, Nektar, Merck, Celgene, and GSK.

Figures

Figure 1.
Figure 1.
Schematic representation of mechanisms through which EGFR TKI resistance emerges through (A) expansion of pre-existing resistant sub-clones or (B) acquisition of resistance conferring alterations by drug tolerant persister cells. Panel (C) is a representation of the mechanism through which osimertinib resistance with T790M loss emerges. e19/21= EGFR exon 19 or 21 mutated.
See this image and copyright information in PMC

Comment on

References

    1. Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, et al. : Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC. Clin Cancer Res, 2018 - PMC - PubMed
    1. Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, et al. : Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol, 2018 - PMC - PubMed
    1. Lin JJ, Shaw AT: Resisting Resistance: Targeted Therapies in Lung Cancer. Trends Cancer 2016; 2:350–364. - PMC - PubMed
    1. Yang Z, Yang N, Ou Q, Xiang Y, Jiang T, Wu X, et al. : Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients. Clin Cancer Res 2018;24:3097–3107. - PubMed
    1. Lee JK, Lee J, Kim S, Kim S, Youk J, Park S, et al. : Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas. J Clin Oncol 2017;35:3065–3074. - PubMed

Publication types